In Week of Mar 28, 2026, Ipca Laboratories Ltd (Pharma - Formulators) is outperforming Nifty 500 with +21.8% relative strength. Fundamentals: Average. On a 5-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Mar 7, 2026
What: 15% chronic segment growth vs 12% IPM driving margin expansion
Impact: +₹300 Cr revenue
“On chronic segment the IPM growth was 12%, Ipca 15% - Ajit Jain, MD & CFO”
What: 17% export growth creating higher-margin revenue mix
Impact: +₹300 Cr revenue
“Our export formulation business in Q3 has delivered a growth of around 17% - Ajit Jain, MD & CFO”
What: Strategic focus on pain, CV and diabetes improving cost-to-sales ratio
“Material costs have stabilized, and the company expects a 3.3%-3.4% improvement in material cost-to-sales ratio for the year - Ajit Jain, MD & CFO”
Earnings deceleration risks from management commentary
Trigger: Continued loss of high-volume US businesses
Impact: -200 bps margin impact
Management view: Unichem's business faced challenges due to the loss of high-volume businesses in the US, impacting margins. However, improvements are expected through better utilization of capacity - Ajit Jain, MD & CFO
Monitor: US business EBITDA margin
Trigger: Failure to regain API growth momentum
Impact: -50 bps margin impact
Management view: API business during the quarter was flat at around 317 cr for 9 months of the current financial year - Ajit Jain, MD & CFO
Monitor: API quarterly growth rate
Key quotes from recent conference calls
“On chronic segment the IPM growth was 12%, Ipca 15% — Ajit Jain”
“Our export formulation business in Q3 has delivered a growth of around 17% — Ajit Jain”
“Material costs have stabilized, and the company expects a 3.3%-3.4% improvement in material cost-to-sales ratio for the year — Ajit Jain”
“There are no major expansion plans except for a solar project with a capital outlay of around INR50 crores — Ajit Jain”
Forward-looking targets from management for next_2-4_quarters
Capex Plan
₹50 Cr
Key Milestones
• US business margin improvement
• European market expansion
• New product launches in US
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +7% | +15% | Decelerating |
| PAT (Net Profit) | +32% | -4% | Stable |
| OPM | 22.0% | +100 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 7, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Ipca Laboratories Ltd's latest quarterly results (Dec 2025) show
Ipca Laboratories Ltd's profit is growing with an stable trend.
Ipca Laboratories Ltd's revenue growth trend is decelerating.
Ipca Laboratories Ltd's operating margin is stable.
Ipca Laboratories Ltd's long-term compounding rates
Ipca Laboratories Ltd's earnings growth is stable with positive momentum on a sequential basis.
Ipca Laboratories Ltd's trailing twelve month (TTM) performance
Ipca Laboratories Ltd appears significantly overvalued based on our fair value analysis.
Ipca Laboratories Ltd's current PE ratio is 38.1x.
Ipca Laboratories Ltd's current PE is 38.1x.
Ipca Laboratories Ltd's price-to-book ratio is 5.4x.
Ipca Laboratories Ltd is rated Average with a fundamental score of 54.78/100. This score is calculated from objective financial metrics
Ipca Laboratories Ltd has a debt-to-equity ratio of N/A.
Ipca Laboratories Ltd's return ratios over recent years
Ipca Laboratories Ltd's operating cash flow is positive (FY2025).
Ipca Laboratories Ltd's current dividend yield is 0.25%.
Ipca Laboratories Ltd's shareholding pattern (Dec 2025)
Ipca Laboratories Ltd's promoter holding has remained stable recently.
Ipca Laboratories Ltd has been outperforming Nifty 500 for 5 consecutive weeks, indicating building momentum.
Ipca Laboratories Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Ipca Laboratories Ltd has 3 key growth catalysts identified from recent earnings analysis
Ipca Laboratories Ltd has 2 key risks worth monitoring
In Q3 FY26, Ipca Laboratories Ltd's management highlighted
Ipca Laboratories Ltd's management has provided the following forward guidance for next_2-4_quarters
Based on quantitative research signals, here is why Ipca Laboratories Ltd may be worth studying
Ipca Laboratories Ltd investment thesis summary:
Ipca Laboratories Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
